← Browse by Condition
Medical Condition

multiple myeloma

Total Trials
57
Recruiting Now
57
Trial Phases
Phase 2, Phase 3, EARLY_Phase 1

ClinicalMetric tracks all active clinical trials for multiple myeloma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — multiple myeloma Clinical Trials

How many clinical trials are currently recruiting for multiple myeloma?
ClinicalMetric currently tracks 57 actively recruiting clinical trials for multiple myeloma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 57. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for multiple myeloma?
multiple myeloma research spans Phase 1 (18 trials), Phase 2 (21 trials), Phase 3 (5 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a multiple myeloma clinical trial?
Eligibility criteria for multiple myeloma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
18
Phase 2
21
Phase 3
5
Phase 4
1
Top Sponsors
Institute of Hematology & Blood Diseases Hospital, China 4 trials
Memorial Sloan Kettering Cancer Center 4 trials
AbbVie 3 trials
Janssen Research & Development, LLC 2 trials
Xuzhou Medical University 2 trials

Recruiting Clinical Trials

NCT05636787 Phase 2
Recruiting
Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients
Enrollment
120 pts
Location
Switzerland
Sponsor
Insel Gruppe AG, University Ho...
View Trial →
NCT05552222 Phase 3
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Enrollment
1,590 pts
Location
United States, Austr...
Sponsor
Janssen Research & Development...
View Trial →
NCT05956457
Recruiting
PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma
Enrollment
100 pts
Location
United States
Sponsor
Pack Health
View Trial →
NCT07249073 EARLY_Phase 1
Recruiting
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Enrollment
9 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT05722405 Phase 4
Recruiting
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
View Trial →
NCT06997081 Phase 2
Recruiting
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Enrollment
104 pts
Location
United States
Sponsor
University of Miami
View Trial →
NCT03412877 Phase 2
Recruiting
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Enrollment
285 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT06784167
Recruiting
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Enrollment
45 pts
Location
United States
Sponsor
OHSU Knight Cancer Institute
View Trial →
NCT03823534 Phase 3
Recruiting
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Enrollment
60 pts
Location
United States
Sponsor
St. Louis University
View Trial →
NCT04645199
Recruiting
National Longitudinal Cohort of Hematological Diseases
Enrollment
2,300 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT07226609
Recruiting
A Dietary Study for People With Multiple Myeloma
Enrollment
220 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT04898790
Recruiting
Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant
Enrollment
114 pts
Location
United States
Sponsor
University of Nebraska
View Trial →
NCT04795882 Phase 1
Recruiting
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Enrollment
27 pts
Location
United Kingdom
Sponsor
University College, London
View Trial →
NCT05646576
Recruiting
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Enrollment
90 pts
Location
United States
Sponsor
Massachusetts General Hospital
View Trial →
NCT05846880 EARLY_Phase 1
Recruiting
VitD3 Supplementation in Patients With Multiple Myeloma
Enrollment
100 pts
Location
United States
Sponsor
Amany Keruakous, MD, MS.
View Trial →
NCT05294055 Phase 2
Recruiting
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Enrollment
120 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT06581640 Phase 2
Recruiting
Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma
Enrollment
5 pts
Location
China
Sponsor
The First Affiliated Hospital ...
View Trial →
NCT06895291
Recruiting
Whole Body MRI in Oncology
Enrollment
1,000 pts
Location
Italy
Sponsor
Istituto Romagnolo per lo Stud...
View Trial →
NCT06896916 Phase 1
Recruiting
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Enrollment
135 pts
Location
United States, Austr...
Sponsor
AbbVie
View Trial →
NCT06323447
Recruiting
Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
Enrollment
210 pts
Location
United States, Spain
Sponsor
Leuko Labs, Inc.
View Trial →
NCT06055894
Recruiting
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
Enrollment
200 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT05137054 Phase 1
Recruiting
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Enrollment
317 pts
Location
United States, Franc...
Sponsor
Regeneron Pharmaceuticals
View Trial →
NCT07489534 Phase 2
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Enrollment
25 pts
Location
China
Sponsor
Daihong Liu
View Trial →
NCT07227311 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Enrollment
200 pts
Location
United States, Franc...
Sponsor
GlaxoSmithKline
View Trial →
NCT06083922 Phase 2
Recruiting
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Enrollment
20 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT06348108 Phase 1
Recruiting
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Enrollment
32 pts
Location
United States
Sponsor
Alfred Chung, MD
View Trial →
NCT00898235
Recruiting
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Enrollment
10,000 pts
Location
United States
Sponsor
Boston Medical Center
View Trial →
NCT06182774 Phase 3
Recruiting
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Enrollment
570 pts
Location
Canada
Sponsor
Canadian Cancer Trials Group
View Trial →
NCT01890486
Recruiting
The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen
Enrollment
2,000 pts
Location
United States
Sponsor
Wake Forest University Health ...
View Trial →
NCT07763054
Recruiting
Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients
Enrollment
30 pts
Location
China
Sponsor
Haikou Affiliated Hospital of ...
View Trial →
NCT07490613 Phase 1
Recruiting
A Phase I Study of SHR-3836 in Patients With Multiple Myeloma
Enrollment
99 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT06988488 Phase 1, Phase 2
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Enrollment
62 pts
Location
United States, Canad...
Sponsor
Celgene
View Trial →
NCT07638683 Phase 2
Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Enrollment
30 pts
Location
China
Sponsor
Shanghai Zhongshan Hospital
View Trial →
NCT06132711 Phase 1, Phase 2
Recruiting
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
Enrollment
20 pts
Location
China
Sponsor
Xuzhou Medical University
View Trial →
NCT07589634 Phase 2
Recruiting
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment
230 pts
Location
United States, Argen...
Sponsor
Janssen Research & Development...
View Trial →
NCT06953960 Phase 1, Phase 2
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Enrollment
325 pts
Location
United States, Austr...
Sponsor
AbbVie
View Trial →
NCT06140966 Phase 2
Recruiting
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Enrollment
54 pts
Location
China
Sponsor
Union Hospital, Tongji Medical...
View Trial →
NCT05650632 Phase 1
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Enrollment
250 pts
Location
United States, Canad...
Sponsor
AbbVie
View Trial →
NCT07403630
Recruiting
INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
Enrollment
300 pts
Location
Italy
Sponsor
Azienda Ospedaliero-Universita...
View Trial →
NCT01408225
Recruiting
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Enrollment
5,000 pts
Location
United States
Sponsor
Ohio State University Comprehe...
View Trial →
NCT07179679 Phase 1
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Enrollment
42 pts
Location
China
Sponsor
Chia Tai Tianqing Pharmaceutic...
View Trial →
NCT05272826 Phase 2
Recruiting
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
Enrollment
75 pts
Location
Canada
Sponsor
Canadian Myeloma Research Grou...
View Trial →
NCT05299424 Phase 1, Phase 2
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Multiple Myeloma
Enrollment
48 pts
Location
China
Sponsor
Keymed Biosciences Co.Ltd
View Trial →
NCT06187441 Phase 3
Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Enrollment
599 pts
Location
Netherlands
Sponsor
Stichting Hemato-Oncologie voo...
View Trial →
NCT06697483
Recruiting
Risk Stratification and MRD-driven Maintenance for MM After ASCT
Enrollment
100 pts
Location
China
Sponsor
Peking University People's Hos...
View Trial →
NCT05405387 Phase 2
Recruiting
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Enrollment
120 pts
Location
United States
Sponsor
University of Utah
View Trial →
NCT07255898 Phase 1
Recruiting
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Enrollment
33 pts
Location
China
Sponsor
Sichuan Baili Pharmaceutical C...
View Trial →
NCT04661137 Phase 2
Recruiting
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Enrollment
96 pts
Location
United States
Sponsor
Hackensack Meridian Health
View Trial →
NCT07249528
Recruiting
A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy
Enrollment
20 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT04888039
Recruiting
Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"
Enrollment
2,000 pts
Location
France
Sponsor
University Hospital, Toulouse
View Trial →
NCT06623630 Phase 1
Recruiting
Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function
Enrollment
16 pts
Location
United States
Sponsor
Washington University School o...
View Trial →
NCT07409454 Phase 2
Recruiting
MRD-Guided BCMA/CD3 Bispecific Antibody Treatment After Stem Cell Transplant for Newly Diagnosed Multiple Myeloma
Enrollment
20 pts
Location
China
Sponsor
Institute of Hematology & Bloo...
View Trial →
NCT06395441 Phase 3
Recruiting
Wisconsin Ginseng for Decreasing Cancer Related Fatigue
Enrollment
222 pts
Location
United States
Sponsor
Mayo Clinic
View Trial →
NCT06759181 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Enrollment
20 pts
Location
China
Sponsor
Xuzhou Medical University
View Trial →
NCT05737732
Recruiting
The Ambient Light Multiple Myeloma Study
Enrollment
200 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo...
View Trial →
NCT06976437 EARLY_Phase 1
Recruiting
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
Enrollment
21 pts
Location
China
Sponsor
YANRU WANG
View Trial →
NCT04776330 Phase 1, Phase 2
Recruiting
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Enrollment
80 pts
Location
China
Sponsor
Chongqing Precision Biotech Co...
View Trial →

Related Conditions

lymphoma (7) chronic lymphocytic leukemia (4) leukemia (3) monoclonal gammopathy of undetermined significance (3) ovarian cancer (2) diffuse large b cell lymphoma (2) acute myeloid leukemia (2) myelodysplastic syndrome (2) al amyloidosis (2) non hodgkin lymphoma (2) relapsed hematologic malignancy (1) endocrine tumors (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology